Sanjiv.Parant, a company in the Pharmaceuticals industry, reported revenue of ₹25 crore and net profit of ₹4.15 crore for the September 2026 quarter.
Sanjiv.Parant. (BSE: SANJIVIN) closed at ₹166.65 on 20 Nov 2026, down 10.1% over the past year. Its market capitalisation is ₹205 crore and it trades at 20.5 times earnings.
Incorporated in 1994, Sanjivani Parenteral Ltd is a research-based and export-oriented pharmaceutical company
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.